• Disease
  • Movement
  • Movement Disorders
  • Joseph J Jankovic

    Prominent publications by Joseph J Jankovic

    KOL Index score: 17367

    BACKGROUND: The ADAGIO study investigated whether rasagiline has disease-modifying effects in Parkinson's disease. Rasagiline 1 mg per day, but not 2 mg per day, was shown to be efficacious in the primary analysis. Here, we report additional secondary and post-hoc analyses of the ADAGIO study.

    METHODS: ADAGIO was a placebo-controlled, double-blind, multicentre, delayed-start study, in which 1176 patients with untreated early Parkinson's disease were randomly assigned to receive ...

    Also Ranks for: Adagio Study |  updrs scores |  36 weeks |  rasagiline placebo |  week difference
    KOL Index score: 16813

    BACKGROUND: A therapy that slows disease progression is the major unmet need in Parkinson's disease.

    METHODS: In this double-blind trial, we examined the possibility that rasagiline has disease-modifying effects in Parkinson's disease. A total of 1176 subjects with untreated Parkinson's disease were randomly assigned to receive rasagiline (at a dose of either 1 mg or 2 mg per day) for 72 weeks (the early-start group) or placebo for 36 weeks followed by rasagiline (at a dose of either 1 ...

    Also Ranks for: 1 Day |  updrs score |  week earlystart |  early treatment |  rasagiline parkinsons disease
    KOL Index score: 15849

    The purpose of this work was to map the entire recognition profile of the H chain of botulinum neurotoxin A (BoNT/A) by Abs in sera that have protective anti-BoNT/A Abs by the mouse protection assay (MPA) from cervical dystonia (CD) patients who had been treated with botulinum neurotoxin, serotype A (BOTOX). In previous studies we found that human anti-tetanus neurotoxin (TeNT) Abs cross-react with BoNT/A and BoNT/B. In the present work we devised an assay procedure for measuring ...

    Also Ranks for: Botulinum Neurotoxin |  cervical dystonia patients |  heavy chain |  antibont abs |  mice mice bont
    KOL Index score: 14977

    IMPORTANCE: We observed a significant correlation between cerebrospinal fluid (CSF) levels of tau proteins and α-synuclein, but not β-amyloid 1-42 (Aβ1-42), and lower concentration of CSF biomarkers, as compared with healthy controls, in a cohort of entirely untreated patients with Parkinson disease (PD) at the earliest stage of the disease studied so far.

    OBJECTIVE: To evaluate the baseline characteristics and relationship to clinical features of CSF biomarkers (Aβ1-42, total tau ...

    Also Ranks for: Synuclein Levels |  parkinson disease |  csf biomarkers |  cerebrospinal fluid |  42 tau
    KOL Index score: 14780

    Biomarkers are urgently needed for the diagnosis and monitoring of disease progression in Parkinson's disease. Both DJ-1 and alpha-synuclein, two proteins critically involved in Parkinson's disease pathogenesis, have been tested as disease biomarkers in several recent studies with inconsistent results. These have been largely due to variation in the protein species detected by different antibodies, limited numbers of patients in some studies, or inadequate control of several important ...

    Also Ranks for: Human Cerebrospinal Fluid |  dj1 alpha |  blood contamination |  parkinsons disease |  patients parkinson
    KOL Index score: 14634

    Parkinson's disease is a genetically complex disorder. Multiple genes have been shown to contribute to the risk of Parkinson's disease, and currently 90 independent risk variants have been identified by genome-wide association studies. Thus far, a number of genes (including SNCA, LRRK2, and GBA) have been shown to contain variability across a spectrum of frequency and effect, from rare, highly penetrant variants to common risk alleles with small effect sizes. Variants in GBA, encoding ...

    Also Ranks for: Age Onset |  lewy body |  parkinson disease |  variants gba |  genetic risk
    KOL Index score: 14580

    Importance: Tourette syndrome is a neurodevelopmental disorder characterized by childhood onset of motor and phonic tics; treatments for tics are associated with safety concerns. Deutetrabenazine is a selective vesicular monoamine transporter 2 inhibitor approved for the treatment of chorea associated with Huntington disease and tardive dyskinesia in adults.

    Objective: To examine whether deutetrabenazine is effective and safe for the treatment of Tourette syndrome in children and ...

    Also Ranks for: Tourette Syndrome |  children adolescents |  dose deutetrabenazine |  primary efficacy point |  week difference
    KOL Index score: 14035

    IMPORTANCE: Deutetrabenazine is a novel molecule containing deuterium, which attenuates CYP2D6 metabolism and increases active metabolite half-lives and may therefore lead to stable systemic exposure while preserving key pharmacological activity.

    OBJECTIVE: To evaluate efficacy and safety of deutetrabenazine treatment to control chorea associated with Huntington disease.

    DESIGN, SETTING, AND PARTICIPANTS: Ninety ambulatory adults diagnosed with manifest Huntington disease and a baseline ...

    Also Ranks for: Huntington Disease |  deutetrabenazine placebo |  patients chorea |  treatment success |  clinical trial
    KOL Index score: 13821

    BACKGROUND: Whether Parkinson disease (PD) and dementia with Lewy bodies (DLB) represent 2 distinct nosologic entities or are diverse phenotypes of Lewy body disease is subject to debate.

    OBJECTIVES: To determine the accuracy of the diagnoses of Lewy body disease, PD, and DLB by validating the clinical diagnoses of 6 neurologists with the neuropathologic findings and to identify early predictors of the diagnoses.

    METHODS: Six raters who were unaware of the neuropathologic diagnoses ...

    Also Ranks for: Lewy Body Disease |  diagnosis dlb |  clinical diagnoses |  clinicopathologic study |  aged parkinson
    KOL Index score: 13707

    Botulinum toxin type A (Dysport) has been shown in European studies to be a safe and effective treatment for cervical dystonia. This multicenter, double-blind, randomized, controlled trial assessed the safety and efficacy of Dysport in cervical dystonia patients in the United States. Eighty patients were randomly assigned to receive one treatment with Dysport (500 units) or placebo. Participants were followed up for 4 to 20 weeks, until they needed further treatment. They were assessed ...

    Also Ranks for: Cervical Dystonia |  botulinum type |  treatment dysport |  placebo participants |  efficacy safety
    KOL Index score: 13609

    This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS), known as the MDS-UPDRS. The UPDRS is the most widely used scale for the clinical study of Parkinson's disease (PD). The MDS previously organized a critique of the UPDRS, which cited many strengths, but recommended revision of the scale to accommodate new advances and to resolve ...

    Also Ranks for: Clinimetric Testing |  movement disorder society |  rating scale |  unified parkinson |  mdsupdrs updrs
    KOL Index score: 13194

    OBJECTIVE: There is a clear need to develop biomarkers for Parkinson disease (PD) diagnosis, differential diagnosis of Parkinsonian disorders, and monitoring disease progression. We and others have demonstrated that a decrease in DJ-1 and/or α-synuclein in the cerebrospinal fluid (CSF) is a potential index for Parkinson disease diagnosis, but not for PD severity.

    METHODS: Using highly sensitive and quantitative Luminex assays, we measured total tau, phosphorylated tau, amyloid beta ...

    Also Ranks for: Disease Diagnosis |  cerebrospinal fluid biomarkers |  multiple atrophy |  csf proteins |  intracellular signaling peptides
    KOL Index score: 12626

    BACKGROUND: Genome-wide association studies (GWAS) in Parkinson's disease have increased the scope of biological knowledge about the disease over the past decade. We aimed to use the largest aggregate of GWAS data to identify novel risk loci and gain further insight into the causes of Parkinson's disease.

    METHODS: We did a meta-analysis of 17 datasets from Parkinson's disease GWAS available from European ancestry samples to nominate novel loci for disease risk. These datasets ...

    Also Ranks for: Risk Loci |  parkinsons disease |  mendelian randomisation |  genetic correlations |  gwas data
    KOL Index score: 12505

    Genetic variation in the leucine-rich repeat and Ig domain containing 1 gene (LINGO1) was recently associated with an increased risk of developing essential tremor (ET) and Parkinson disease (PD). Herein, we performed a comprehensive study of LINGO1 and its paralog LINGO2 in ET and PD by sequencing both genes in patients (ET, n = 95; PD, n = 96) and by examining haplotype-tagging single-nucleotide polymorphisms (tSNPs) in a multicenter North American series of patients (ET, n = 1,247; ...

    Also Ranks for: Essential Tremor |  lingo2 variants |  parkinson disease |  age onset |  genetic variation
    KOL Index score: 12094

    To improve the specificity and sensitivity of the clinical diagnosis of progressive supranuclear palsy (PSP, Steele-Richardson-Olszewski syndrome), the National Institute of Neurological Disorders and Stroke (NINDS) and the Society for PSP, Inc. (SPSP) sponsored an international workshop to develop an accurate and universally accepted set of criteria for this disorder. The NINDS-SPSP criteria, which were formulated from an extensive review of the literature, comparison with other ...

    Also Ranks for: Criteria Psp |  progressive supranuclear |  olszewski syndrome |  year onset |  prominent postural instability


    Joseph J Jankovic: Influence Statistics

    Sample of concepts for which Joseph J Jankovic is among the top experts in the world.
    Concept World rank
    gaitrite items gabs #1
    ipsilateral tremor #1
    bont cell responses #1
    etm1234 p00001 #1
    participants rotigotine #1
    bont dystonia #1
    ptosis improvement #1
    coprophenomena tourette syndrome #1
    psychogenic tics 06 #1
    welding manganese #1
    subsequent injections patients #1
    apo levodopa doses #1
    visit onset #1
    18 years onset #1
    eopd heterozygous mutations #1
    ht likelihood #1
    variables 3 months #1
    intervals 12 weeks #1
    prx002 patients #1
    autophagy induction resveratrol #1
    ipmds #1
    orthostatic hypotension placebo #1
    pallidotomy outcomes #1
    study deutetrabenazine #1
    chapter 19 movements #1
    botulinum toxin conditions #1
    ocb add #1
    voice disorders patients #1
    phonic #1
    dopamine depleters #1
    blepharospasm xeomin #1
    cranialcervical dystonia bruxism #1
    stimulation threshold safety #1
    glutamatargics #1
    loci d2s2150 #1
    depression 151 #1
    disorders clinic #1
    nkx2‐1 mutations #1
    families etm locus #1
    dysport participants #1
    longterm safety tolerability #1
    agents dystonia #1
    range 1 day #1
    26–43 #1
    dystonia chorea #1
    peptides c10 #1
    rs733731 #1
    apraclonidine blepharospasm #1
    children essential tremor #1

    Key People For Movement Disorders

    Top KOLs in the world
    Anthony Edward Lang
    parkinson disease movement disorders subthalamic nucleus
    Joseph J Jankovic
    movement disorders parkinson disease essential tremor
    Khailash P Bhatia
    movement disorders cervical dystonia parkinson disease
    HALLETT Hallett
    essential tremor motor cortex magnetic stimulation
    Stanley Fahn
    parkinson disease movement disorders botulinum toxin
    C David Marsden
    parkinsons disease basal ganglia substantia nigra

    Joseph J Jankovic:Expert Impact

    Concepts for whichJoseph J Jankovichas direct influence:Movement disorders,  Parkinson disease,  Essential tremor,  Tourette syndrome,  Cervical dystonia,  Botulinum toxin,  Parkinsons disease,  Deep brain stimulation.

    Joseph J Jankovic:KOL impact

    Concepts related to the work of other authors for whichfor which Joseph J Jankovic has influence:Parkinson disease,  Botulinum toxin,  Essential tremor,  Movement disorders,  Deep brain stimulation,  Tourette syndrome,  Cervical dystonia.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA | Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Housto